Constitutive activation of liver kinase B1/AMP-activated protein kinase (LKB1/AMPK) pathway in KO livers The resistance of KO mice to steatosis induced by chronic EtOH consumption suggests low hepatic GSH elicits a protective metabolic adaption in the liver
However, no standard preventive therapy currently exists
Im also very much unenhanced
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
Using endogenous antioxidant above may have already given away the answer
ChaC2 is a constitutively expressed protein whose expression is not affected by the external environment for the basal turnover of GSH [37]